The Race To Regulatory Approval: Delivering Critical Therapies With Speed And Safety

Speeding critical therapies to market now requires a regulatory strategy to shape development from the start—not wait until final submission. With only 25–30% of candidates advancing through all three clinical trial phases and just 30–40% of those moving on to NDA or BLA submission, preventable gaps such as weak risk management, inconsistent manufacturing, incomplete documentation, and missed agency guidance can quickly become costly delays. A stronger path forward pairs adaptable trial design with scalable, cGMP-ready materials, resilient supply planning, and supplier partnerships that support traceability, documentation, and site-to-site consistency. Regular agency engagement and region-specific planning can further strengthen submissions and create faster routes to global markets.

Access the full white paper to learn practical ways to embed regulatory readiness into every stage of development.